Jeff Knight serves as the Chief Operating Officer (COO) at Crinetics Pharmaceuticals Inc., a biopharmaceutical company focused on developing novel therapeutics for rare endocrine diseases and endocrine-related tumors. In his role as COO, Knight is responsible for overseeing the company's operational strategies and ensuring that Crinetics meets its business objectives while maintaining compliance with industry standards. His leadership is instrumental in driving the company's growth and advancing its mission to bring innovative treatments to patients in need. Knight brings a wealth of experience to Crinetics, with a strong background in the pharmaceutical and biotechnology sectors. Prior to joining Crinetics, he held several senior leadership positions at various life sciences companies, where he demonstrated a proven track record of successfully managing complex projects and teams. His expertise spans across drug development, manufacturing, and commercialization, making him a valuable asset to Crinetics as the company progresses its pipeline of promising drug candidates. Under Knight's guidance, Crinetics has made significant strides in its development programs, particularly with its lead candidate, paltusotine, which is being investigated for the treatment of acromegaly and carcinoid syndrome. His strategic vision and operational acumen have been crucial in navigating the challenges of clinical development and positioning Crinetics for future success. Knight's commitment to excellence and patient-centric approach continue to shape the company's culture and drive its mission forward.